SGK1在前列腺癌中的表达及其临床意义

Expression and clinical significance of SGK1 in prostate cancer

目的探讨血清/糖皮质激素调节激酶1(SGK1)在前列腺癌中的表达及与临床病理特征和预后的关系。方法应用免疫组织化学方法检测SGK1在前列腺癌组织中的表达情况,并进一步分析其表达与临床病理征和预后的关系。结果SGK1在前列腺癌组织中表达阳性率58%.前列腺癌组织中SGK1表达与患者术前是否行ADT治疗(P<0.001)、肿瘤Gleason分级(P=0.013)和临床分期(P<0.001)呈正相关关系。Kaplan-Meier生存分析显示,SGK1表达与患者PSA无进展生存无相关性(P=0.126),但SGK1表达与患者总生存期相关,与低表达组比较,高表达组总生存时间更短(P=0.011)。多因素COX回归分析表明,SGK1表达是前列腺癌患者总生存率的独立影响因素。结论SGK1在前列腺癌中表达与肿瘤发生、进展和患者不良预后密切相关。SGK1有望成为一种新的前列腺癌治疗的有效靶点和预后预测的生物标志物。

Objective To investigate the expression of SGK1 in prostate cancer tissues and analyze the correlations with clinicopathologic characteristics and prognosis.Methods The expression of SGK1 in prostate cancer tissues was determined by immunohistochemistry staining and the correlations between the expression of SGK1 and clininicalpathological parameters,including prognostic significance were analyzed.Results The positivity rate of SGK1 expression in prostate cancer tissues was 58%.SGK1 expression was positively correlated with ADT treatement(P<0.001),Gleason classification(P=0.013)and clinical stage(P<0.001).Kaplan-Meier analysis revealed that the expression of SGK1 was not correlated with the PSA progression free survival(P=0.126),but it was correlated with the overall survival rate of prostate cancer patients,compared with the patients with low SGK1 expressions,patients with high SGK1 expression had a worse overall survival rate(P=0.011).Multivariate COX regression analysis showed that the expression of SGK1 was independently associated with the OS of the patient with prostate cancer.Conclusion The expression of SGK1 is closely related to the tumorigenesis and progression and poor prognosis in prostate cancer.SGK1 might be a new effective target of treatment and a prognostic biomarker in prostate cancer.